NASDAQ:ARVN

Arvinas - ARVN Stock Forecast, Price & News

$26.45

+0.11 (+0.42%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $25.35
▼
$26.51
50-Day Range: $26.34
▼
$37.26
52-Week Range: $25.35
▼
$75.39

Volume: 577,863 shs
Average Volume: 449,199 shs
Market Capitalization: $1.41 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $68.75

Institutional Ownership

Arvinas MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.72 Rating Score
Upside/Downside: 159.9% Upside
$68.75 Price Target
Short Interest: Bearish
11.09% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.26
Based on 3 Articles This Week
Insider Trading: Selling Shares
$256,143 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($6.01) to ($7.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

645th out of 1,005 stocks

Pharmaceutical Preparations Industry

309th out of 486 stocks

4.4

Analyst's Opinion

Consensus Rating
Arvinas has received a consensus rating of Buy. The company's average rating score is 2.72, and is based on 13 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $68.75, Arvinas has a forecasted upside of 159.9% from its current price of $26.45.
Amount of Analyst Coverage
Arvinas has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
11.09% of the float of Arvinas has been sold short.
Short Interest Ratio / Days to Cover
Arvinas has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Arvinas has recently increased by 6.51%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Arvinas does not currently pay a dividend.
Dividend Growth
Arvinas does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARVN.

2.4

News and Social Media Coverage

News Sentiment
Arvinas has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Arvinas this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
5 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $256,143.00 in company stock.
Percentage Held by Insiders
Only 2.78% of the stock of Arvinas is held by insiders.
Percentage Held by Institutions
92.03% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Arvinas are expected to decrease in the coming year, from ($6.01) to ($7.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arvinas is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arvinas is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arvinas has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

March 23, 2023 | americanbankingnews.com

Analysts Set Arvinas, Inc. (NASDAQ:ARVN) PT at $68.44

March 21, 2023 | americanbankingnews.com

Arvinas (NASDAQ:ARVN) Given New $77.00 Price Target at Citigroup

March 26, 2023 | Stansberry Research (Ad)

The gold catalyst we’ve waited for

If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.

March 17, 2023 | americanbankingnews.com

Arvinas, Inc. (NASDAQ:ARVN) Short Interest Up 6.5% in February

February 24, 2023 | finance.yahoo.com

Arvinas Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

February 24, 2023 | finance.yahoo.com

A Look At The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

February 6, 2023 | finance.yahoo.com

Arvinas to Participate in Upcoming Investor Conferences

January 11, 2023 | finance.yahoo.com

Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock?

March 26, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

January 4, 2023 | finance.yahoo.com

Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023 | finance.yahoo.com

Investors in Arvinas (NASDAQ:ARVN) from a year ago are still down 57%, even after 5.4% gain this past week

December 31, 2022 | finance.yahoo.com

Arvinas, Inc. (ARVN) Stock Historical Prices & Data - Yahoo Finance

November 22, 2022 | finance.yahoo.com

Arvinas's ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer Setting

November 10, 2022 | markets.businessinsider.com

SVB Securities Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)

November 1, 2022 | finance.yahoo.com

Arvinas to Present at Upcoming Conferences

November 1, 2022 | finance.yahoo.com

Why Arvinas (ARVN) Might Surprise This Earnings Season

October 10, 2022 | reuters.com

ARVN.N - Arvinas Inc | Stock Price & Latest News | Reuters

October 4, 2022 | businesswire.com

Secretome Therapeutics Announces Appointment of Angela Shen, M.D., M.B.A., to Board of Directors - Business Wire

October 3, 2022 | finance.yahoo.com

Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

September 30, 2022 | globenewswire.com

Arvinas Gives Back to Local Greater New Haven Community - GlobeNewswire

September 30, 2022 | finance.yahoo.com

Arvinas Gives Back to Local Greater New Haven Community

September 26, 2022 | globenewswire.com

Arvinas to Present at Bank of America Securities Precision Oncology Conference - GlobeNewswire

September 26, 2022 | finance.yahoo.com

Arvinas to Present at Bank of America Securities Precision Oncology Conference

September 14, 2022 | streetinsider.com

Pardes Biosciences (PRDS) Appoints Laurie Smaldone Alsup and John C. Pottage to its Board - StreetInsider.com

September 13, 2022 | benzinga.com

Arvinas (NASDAQ:ARVN) – hC Bioscience Appoints Brad Margus to its Board of Directors - Benzinga

September 9, 2022 | benzinga.com

Arvinas (NASDAQ:ARVN) – Where Arvinas Stands With Analysts - Benzinga

September 9, 2022 | seekingalpha.com

ARVN stock initiated Overweight at Barclays on therapeutic platform (NASDAQ:ARVN) - Seeking Alpha

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Company Calendar

Last Earnings: 2/23/2023
Today: 3/26/2023
Next Earnings (Estimated): 5/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARVN
CUSIP: N/A
CIK: 1655759
Web: www.arvinas.com
Phone: (203) 535-1456
Fax: N/A
Employees: 280
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $68.75
High Stock Price Forecast: $95.00
Low Stock Price Forecast: $27.00
Forecasted Upside/Downside: +159.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.72
Research Coverage: 18 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-282,500,000.00
Net Margins: -228.19%
Pretax Margin: -191.02%
Return on Equity: -43.79%
Return on Assets: -20.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.20
Quick Ratio: 4.20

Sales & Book Value

Annual Sales: $131.40 million
Price / Sales: 10.72
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.61 per share
Price / Book: 2.49

Miscellaneous

Outstanding Shares: 53,270,000
Free Float: 51,790,000
Market Cap: $1.41 billion
Optionable: Not Optionable
Beta: 1.78

Key Executives

John G. Houston
President, Chief Executive Officer & Director

Lisa Sinclair
Senior Vice President-Corporate Operations

Sean A. Cassidy
Chief Financial Officer

Ian Taylor
Chief Scientific Officer

Ronald Peck
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARVN Stock - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?: 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.
What is Arvinas' stock price forecast for 2023?: 18 Wall Street analysts have issued 12 month price targets for Arvinas' shares. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they expect the company's stock price to reach $68.75 in the next twelve months. This suggests a possible upside of 159.9% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.
How have ARVN shares performed in 2023?: Arvinas' stock was trading at $34.21 on January 1st, 2023. Since then, ARVN stock has decreased by 22.7% and is now trading at $26.45.
View the best growth stocks for 2023 here.
When is Arvinas' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ARVN earnings forecast.
How were Arvinas' earnings last quarter?: Arvinas, Inc. (NASDAQ:ARVN) released its quarterly earnings results on Thursday, February, 23rd. The company reported ($1.56) EPS for the quarter, missing analysts' consensus estimates of ($1.10) by $0.46. The firm earned $38 million during the quarter, compared to analyst estimates of $35.32 million. Arvinas had a negative net margin of 228.19% and a negative trailing twelve-month return on equity of 43.79%. The business's revenue was up 32.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.00) EPS.
What ETFs hold Arvinas' stock?: ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), Harbor Disruptive Innovation ETF (INNO) and BlackRock Future Health ETF (BMED).
What other stocks do shareholders of Arvinas own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?: (ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.
What is Arvinas' stock symbol?: Arvinas trades on the NASDAQ under the ticker symbol "ARVN."
Who are Arvinas' major shareholders?: Arvinas' stock is owned by many different retail and institutional investors. Top institutional investors include Avidity Partners Management LP (9.30%), Price T Rowe Associates Inc. MD (4.45%), JPMorgan Chase & Co. (3.70%), ArrowMark Colorado Holdings LLC (2.25%), T. Rowe Price Investment Management Inc. (2.17%) and American Century Companies Inc. (1.74%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends.
How do I buy shares of Arvinas?: Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arvinas' stock price today?: One share of ARVN stock can currently be purchased for approximately $26.45.
How much money does Arvinas make?: Arvinas (NASDAQ:ARVN) has a market capitalization of $1.41 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.32) on an earnings per share basis.
How many employees does Arvinas have?: The company employs 280 workers across the globe.
How can I contact Arvinas?: Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.

This page (NASDAQ:ARVN) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arvinas - ARVN Stock Forecast, Price & News

Arvinas MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Arvinas (NASDAQ:ARVN) Stock

ARVN Stock News Headlines

ARVN Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ARVN Stock - Frequently Asked Questions

Overall MarketRank^™